Table S1.
Construct | Gene(s) | Vector | Affinity tag | Tag position | Expression |
pCB98 | 43 | pCDF1b | — | — | Insoluble |
pCB40 | 44 | pCDF1b | His6 | N-terminal | Soluble |
pCB94 | 46 | pAD100 | — | — | No |
pCB101 | 46 | pCDF1b | — | — | Insoluble |
pCB6 | 47 | pET32b* | Trx-His6-TEV | N-terminal | Soluble |
pCB68 | 47 | pCDF1b | — | — | Soluble |
pCB15 | 48 | pAD100 | FLAG-His6 | C-terminal | No |
pCB44 | 48 | p15TV-L | His6-TEV | N-terminal | Insoluble |
pCB108 | 48 | pCDF1b | — | — | No, reduced culture growth |
pCB119 | 43–44 | pCDF1b | — | — | Soluble, Mup43, -44 |
pCB82 | 43–44–45–46–47–48 | pAD100 | FLAG-His6 | C-terminal | Soluble, Mup43, -44, -46, -47, -48; 45† |
pCB83 | 44–45–46–47–48 | pAD100 | FLAG-His6 | C-terminal | Soluble, Mup44, -46, -47, -48 |
pCB85 | 46–47–48 | pAD100 | FLAG-His6 | C-terminal | Soluble, Mup46, -47, -48 |
pCB111 | 46–47–48 | p15TV-L | His6-TEV | N-terminal | Soluble, Mup46, -47, -48 |
pCB14 | 47–48 | pAD100 | FLAG-His6 | C-terminal | Soluble, Mup47, -48 |
pCB63 | 47–48 | pET32b* | Trx-His6-TEV | N-terminal | Soluble, Mup47, -48 |
pCB100 | 43–44–46–47–48 | pCB85‡ | FLAG-His6 | C-terminal | Soluble, Mup43, -44, -46, -47, -48 |
pCB105 | 43–44–45–46–47–48–49–50 | p15TV-L | His6-TEV | N-terminal | Soluble, Mup43, -44, -46, -47, -48, -49 ,-50 |
pCB127 | 43–44–45–46–47–48–49–50 | pAD100 | His6 | N-terminal | Soluble, Mup43, -44, -46, -47, -48, -49, -50 |
Vector backbones pCDF1b and pET21d (EMD Millipore), pAD100 (33), p15TV-L (Clinical Genomics Centre, University Health Network, Toronto, ON, Canada). Tagged ORF in multicistronic constructs are underlined. His6, hexahistidine tag; Trx, thioredoxin tag.
Modified expression vector pET32b (Novagen), enterokinase protease cleavage site replaced with tobacco virus etch (TEV) protease site.
Detected upon cross-linking.
Cloned into 5′ NcoI site, introducing a 3′ ribosome binding site.